ACM
BCAB icon

Altium Capital Management’s BioAtla BCAB Stock Holding History

Altium Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,060
Closed -$4.26M – 102
2022
Q3 		$4.26M Buy
+11,060
New +$3.62M 1.56% 16

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Altium Capital Management's BCAB Position: Q4 2022 in Review

Altium Capital Management sold out of BioAtla (BCAB) in Q4 2022, closing a stake of 11,060 shares — an estimated $4.26M sold.

Altium Capital Management first reported a position in BCAB in Q3 2022 and held it in 1 quarter. The position peaked at $4.26M in Q3 2022. 91 funds tracked by Wall St. Rank hold BCAB as of Q4 2022.

  • Altium Capital Management reported no remaining BioAtla position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 11,060 BioAtla shares in Q4 2022, an estimated $4.26M.
  • Altium Capital Management first reported a position in BioAtla in Q3 2022 and held it in 1 quarter.
  • Altium Capital Management's BioAtla position peaked at $4.26M in Q3 2022.
  • 91 funds tracked by Wall St. Rank held BioAtla as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.